Navigation Links
Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease
Date:6/9/2011

#174; in the U.S. - Important Safety Information

Some patients treated with Neupro® reported falling asleep while engaged in activities of daily living, including operation of motor vehicles, which sometimes resulted in accidents. Some patients perceived no warning signs, such as excessive drowsiness. Hallucinations were reported in 2.0% of patients treated with Neupro® compared to 0.7% of patients on placebo. Neupro® contains metabisulfite. Neupro® should be used with caution in patients, especially those at risk for cardiovascular disease, because of the potential for symptomatic hypotension, syncope, elevated heart rate, elevated blood pressure, fluid retention, and/or weight gain. All Parkinson's disease patients are at a higher risk for melanoma and should be monitored regularly. The most commonly reported side effects in clinical trials were nausea, application site reactions, somnolence, dizziness, headache, vomiting, and insomnia. Some subjects who received Neupro® experienced a decline in blood hemoglobin levels (about 2% relative to subjects who received placebo). It is not known whether this change is readily reversible with discontinuation of Neupro®.  Please go to http://www.neupro.com/documents/Neupro_PI_071207.pdf for US Full Prescribing Information. 

Neupro® is a registered trademark of the UCB Group of companies.

About rotigotine transdermal system in Canada

Rotigotine transdermal system is not authorized for sale in Canada.

For further information
Nancy Nackaerts, External Communications, UCB
T +32.473.864.414, nancy.nackaerts@ucb.com

Eimear O'Brien, Associate Director, Global CNS Communicat<
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... MONROVIA, Calif., July 29, 2015  STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today reported ... Second Quarter Overview , Net Sales ... , Unfavorable Currency Impact of $2.1 Million from the ... in EMEA and 13% in China , APAC Sales ...
(Date:7/29/2015)... , July 29, 2015 Varian Medical Systems, Inc., ... one of its European subsidiaries, agreed to acquire Claymount, ... components and subsystems for X-ray imaging equipment manufacturers. Varian,s subsidiary ... approximately €50 million in cash for Claymount. The transaction ... Claymount is one of the world,s leading suppliers ...
(Date:7/29/2015)... 29, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the second quarter ended June 30, 2015. ... HETLIOZ and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s ... life cycle management of our products set the stage ... Financial Highlights , Total net product ...
Breaking Medicine Technology:STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 2Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 3Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10
... , LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June ... American Diabetes Association 69th Scientific Sessions in New Orleans show ... reduced blood glucose levels and provided weight loss across weekly, ... key part of managing type 2 diabetes, a disease that ...
... RIDGEFIELD, Conn., June 6 Boehringer Ingelheim Pharmaceuticals, Inc. ... itself in the type 2 diabetes therapeutic area. ... Phase III clinical development worldwide. New Phase II ... 4 (DPP-4) inhibitor and the Company,s lead diabetes compound, ...
Cached Medicine Technology:Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 2Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 3Boehringer Ingelheim Unveils Diabetes Pipeline 2Boehringer Ingelheim Unveils Diabetes Pipeline 3Boehringer Ingelheim Unveils Diabetes Pipeline 4Boehringer Ingelheim Unveils Diabetes Pipeline 5
(Date:7/30/2015)... ... ... Summer is the dry eye season, especially in parts of the country ... hot 2015 summer season and the dry eye rate in the hot spots and ... 2015 summer season and identify the primary dry eye hot spots on her upcoming ...
(Date:7/30/2015)... ... 30, 2015 , ... HEALTHCAREfirst , the leading provider of cloud-based software, ... is hosting a free webinar detailing the 2016 proposed rule from CMS for home ... Vice President of Regulatory Affairs for the National Association for Home Care and Hospice ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... At the presentation of the 2015 Annual ... was focused on research presented by the Journal of Arthroplasty pertaining to how ... like driving. , Results of the study confirm what Santa Rosa Orthopaedics (SRO) ...
(Date:7/30/2015)... ... July 30, 2015 , ... Diagnotes, ... and reporting for reimbursement from the Centers for Medicare & Medicaid Services (CMS) ... providers are experimenting with manual data capture or, in many cases, just deciding ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Addictions Training ... courses for people to become Certified Alcohol and Substance Abuse Counselors. , "We are ... . “There is an acute shortage of Alcohol and Drug Counselors nationwide. ...
Breaking Medicine News(10 mins):Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Diagnotes Announces Expansion of its Mobile Healthcare Communication System to Include Chronic Care Management Reimbursement Support 2Health News:Diagnotes Announces Expansion of its Mobile Healthcare Communication System to Include Chronic Care Management Reimbursement Support 3Health News:Addictions Training Institute Announces New Online Certificate Program for Alcohol and Drug Counselors 2
... bacteria, scientists had been able to use light as ... cavity. ,The dental samples obtained from patients suffering ... to 520nm). The light had selectively killed oral black-pigmented ... samples obtained from patients. Medium strength light had killed ...
... team from the University of Western Ontario had found out that ... ,The study used a robot arm to show how ... the video of this learning process was shown to a group, ... the people in the video. Moreover people who learned the same ...
... scientists, consuming food with high glycemic index have been //linked ... which had spanned 16.6 years and observed the incidence of ... is much significant for women who are past their menopause. ... foods that have simple carbohydrates and sugars like refined flour, ...
... can lead to mothers being less emotionally involved with ... a new study done by researchers of Pennsylvania State ... pregnancy and childbirth was previously related to post-partum depression ... The new study suggests that bonding with their newborns ...
... the second phase of testing of the vaccine for ... cancers and 90% of genital warts. ,277 women ... months and regularly had gynecological examination, cervicovaginal sampling for ... to HPV. , ,The results showed the incidence ...
... the pattern of rising early from bed in the mornings ... ,The behavior is called familial advanced sleep phase ... is said to be the phenotype of the gene PER2. ... the phosphorylation site in the casein kinase I (CKI) domain ...
Cached Medicine News:
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Classic proven design with superior clinical results....
Dual offset femoral stems, hip stems that provide unique and competitive features....
The Perfecta RS Stems utilize the same proven proximal Tri/Planar wedge geometry, medial flare options and proximal coatings of the Perfecta Plasma Spray Stems....
Medicine Products: